Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT03470480

rTMS for Craving in Methamphetamine Use Disorder

Led by Oregon Health and Science University · Updated on 2024-05-17

50

Participants Needed

1

Research Sites

394 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary aim of this project is to use a randomized single-blind sham-controlled study to investigate if high frequency repetitive transmagnetic stimulation (HF-rTMS) can modulate cue-induced craving in adult methamphetamine (METH) users. The investigators hypothesize that HF-rTMS directed at left dorsolateral prefrontal cortex (DLPFC) will result in a reduction in craving for METH compared to sham-controlled rTMS in adults with methamphetamine use disorder (MUD) as evidenced by validated measures of METH craving. Neurobiologically, the investigators anticipate rTMS mediated stimulation of the DLPFC could result in inhibition of cue-induced craving through potential disruption of involved circuitry. The current project proposes that participants who are recently abstinent from METH will be randomized into four experimental groups to provide two rTMS conditions (real versus sham) and two picture cues conditions (METH versus neutral). The experiment will have an induction phase where each subject will receive 10 daily treatments within 2 weeks. Just before each rTMS/sham session participants will be shown visual cues (METH or neutral). Participants will then undergo a maintenance phase for an additional month with assessments to evaluate craving and relapse. Urine samples for urine drug screening (UDS) will be collected at screening day and on days 1, 5 and 10. Just before each rTMS/sham session participants will be shown visual cues (METH and neutral). VAS craving scores will be assessed before and after picture presentation and after the rTMS/sham session. Before the first and 10th treatment session, participants were evaluated by the the Stimulant Craving Questionnaire (STCQ) and the Severity of Dependence Scale (SDS) questionnaires. Participants will then undergo a maintenance phase for an additional month. During the first week of maintenance, three rTMS/sham sessions will be administered. During each of the following 3 weeks, one rTMS/sham session will be given per week. As with the induction phase, urine samples will be collected for screening and STCQ and the SDS questionnaires will be completed at each maintenance session. To evaluate the long-term effects of the rTMS treatment, the investigators plan on contacting participants 6 months after treatment termination for all subjects who completed the 10 treatment sessions. During that phone conversation, craving and relapse will again be assessed.

CONDITIONS

Official Title

rTMS for Craving in Methamphetamine Use Disorder

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Use at least 0.5 grams of methamphetamine per day at least 5 days per week for at least 12 months
  • Meet DSM V diagnosis for methamphetamine use disorder
  • Have been abstinent for at least 4 weeks and want to stop using methamphetamine
Not Eligible

You will not qualify if you...

  • Have or had a neurological disorder
  • Have a primary psychiatric disorder other than methamphetamine use disorder or mild depressive symptoms (Hamilton Depression Scale Score less than 7)
  • Have a Hamilton Depression Scale Score greater than 8
  • Currently abuse drugs other than methamphetamine and nicotine
  • Have cannabis use disorder or alcohol use disorder
  • Have medical illnesses affecting brain function
  • Have a history of cardiovascular disease or high blood pressure
  • Have a history of epilepsy or seizure disorder
  • Have metal in the head or chest area (except dental fillings or braces)
  • Currently use psychiatric medications
  • Have any other medical, neurological, or neurosurgical condition preventing rTMS treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Veterans Affairs Portland Health Care System

Portland, Oregon, United States, 97239

Actively Recruiting

Loading map...

Research Team

B

Brandon J Cornejo, MD, PhD

CONTACT

H

Holly McCready

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here